TY - JOUR
T1 - Use of Artificial Intelligence to Identify New Mechanisms and Approaches to Therapy of Bone Disorders Associated With Chronic Kidney Disease
AU - Gaweda, Adam E.
AU - Lederer, Eleanor D.
AU - Brier, Michael E.
N1 - Publisher Copyright:
Copyright © 2022 Gaweda, Lederer and Brier.
PY - 2022/3/25
Y1 - 2022/3/25
N2 - Chronic kidney disease (CKD) leads to clinically severe bone loss, resulting from the deranged mineral metabolism that accompanies CKD. Each individual patient presents a unique combination of risk factors, pathologies, and complications of bone disease. The complexity of the disorder coupled with our incomplete understanding of the pathophysiology has significantly hampered the ability of nephrologists to prevent fractures, a leading comorbidity of CKD. Much has been learned from animal models; however, we propose in this review that application of multiple techniques of mathematical modeling and artificial intelligence can accelerate our ability to develop relevant and impactful clinical trials and can lead to better understanding of the osteoporosis of CKD. We highlight the foundational work that informed our current model development and discuss the potential applications of our approach combining principles of quantitative systems pharmacology, model predictive control, and reinforcement learning to deliver individualized precision medical therapy of this highly complex disorder.
AB - Chronic kidney disease (CKD) leads to clinically severe bone loss, resulting from the deranged mineral metabolism that accompanies CKD. Each individual patient presents a unique combination of risk factors, pathologies, and complications of bone disease. The complexity of the disorder coupled with our incomplete understanding of the pathophysiology has significantly hampered the ability of nephrologists to prevent fractures, a leading comorbidity of CKD. Much has been learned from animal models; however, we propose in this review that application of multiple techniques of mathematical modeling and artificial intelligence can accelerate our ability to develop relevant and impactful clinical trials and can lead to better understanding of the osteoporosis of CKD. We highlight the foundational work that informed our current model development and discuss the potential applications of our approach combining principles of quantitative systems pharmacology, model predictive control, and reinforcement learning to deliver individualized precision medical therapy of this highly complex disorder.
KW - artificial intelligence
KW - chronic kidney disease
KW - in silico clinical trials
KW - mathematical modeling
KW - osteoporosis
UR - http://www.scopus.com/inward/record.url?scp=85128265150&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85128265150&partnerID=8YFLogxK
U2 - 10.3389/fmed.2022.807994
DO - 10.3389/fmed.2022.807994
M3 - Review article
C2 - 35402468
AN - SCOPUS:85128265150
SN - 2296-858X
VL - 9
JO - Frontiers in Medicine
JF - Frontiers in Medicine
M1 - 807994
ER -